Do hearing aids prevent cognitive decline? What ACHIEVE actually found

Hearing care matters, but the major trial was null overall. Understand its higher-risk subgroup and a 2025 analysis without a dementia-prevention promise.

Prepared by PoshanSense · AI-assisted educational writing
Our sources and editorial approach · Not clinically reviewed

Research explained · Published 2023, 2025

A hearing-aid headline can sound wonderfully simple: improve hearing, protect memory. The trial behind that headline tells a more useful story about who was studied, what changed, and what hearing care is actually for.

Should memory protection be the main reason to get hearing aids?

The strongest answer is to start with your hearing needs. Understanding conversations, participating in gatherings and communicating with other people are practical reasons to seek assessment. The cognitive findings add an interesting possibility for some older adults, but they do not promise that a device will prevent dementia.

That distinction also avoids an unfair conclusion: a person who develops dementia has not necessarily failed to address hearing loss. Brain health has many determinants, and this trial did not settle all of them.

Why did the headlines mention a large benefit?

The primary ACHIEVE report combined two recruitment groups. In all 977 participants, the difference in three-year cognitive change was essentially zero: 0.002 standardized units, with an uncertainty interval spanning benefit and harm.

A prespecified analysis separated the 238 people recruited from the long-running ARIC cohort from 739 newly recruited volunteers. ARIC participants were generally older, had more cognitive-risk factors and declined faster in the control group. Hearing care was associated with 48% slower decline in that ARIC subgroup; the newly recruited group had no clear benefit.

That percentage describes change in a cognitive score within one subgroup. It does not mean 48% fewer dementia diagnoses, and it is not a prediction for every hearing-aid user.

What does the 2025 paper add?

A secondary analysis built a risk model using 2,692 separate ARIC participants and applied it to the same 977 ACHIEVE participants. In the highest predicted-risk quarter, cognitive decline was about 62% slower with hearing care. The estimate had a wide uncertainty interval, and the model overestimated decline in the trial population.

This strengthens the question of whether baseline risk matters. It remains a reanalysis, rather than a second trial independently reproducing the result. It also does not turn a collection of risk factors into a reliable online test of who will benefit.

Would an inexpensive hearing aid give the same result?

The intervention included audiological counselling, fitting and ongoing support. It was not simply a parcel containing a device. The evidence cannot tell us that every product, fit or level of use produces the same cognitive outcome.

The trial also studied people aged 70–84 with untreated hearing loss and no substantial cognitive impairment. It cannot establish a dementia treatment or automatically answer the same question for younger adults.

A sensible next step

If hearing is making everyday life difficult, discuss assessment and suitable support with a qualified hearing professional. Keep the decision grounded in communication, comfort and actual hearing needs. Treat the cognitive findings as promising but conditional, rather than an obligation to purchase a particular brand.

The trial received US National Institutes of Health funding. Sonova/Phonak supplied hearing technologies in kind, and several authors disclosed industry relationships. Those disclosures deserve visibility; they do not erase the randomized result or its limits. Educational article; not clinically reviewed.

Published 11 October 2026 · Sources checked 11 October 2026. Suggest a correction.